2025 has proven to be another year of excellent execution, both financially and operationally. Cresemba delivered another strong financial performance, generating total revenue of CHF232.4m, ahead of our expectations (CP CHF225m). Royalty income increased by 15.4% to CHF111.6m, with costs carefully controlled. Basilea ended the year with a strong balance sheet and net cash CHF 86.9m.
17 Feb 2026
Basilea Full Year 2025 Results
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Basilea Full Year 2025 Results
Basilea Pharmaceutica AG (BSLN:SWX) | 0 0 0.0%
- Published:
17 Feb 2026 -
Author:
Brian White | Andrew Keith -
Pages:
4 -
2025 has proven to be another year of excellent execution, both financially and operationally. Cresemba delivered another strong financial performance, generating total revenue of CHF232.4m, ahead of our expectations (CP CHF225m). Royalty income increased by 15.4% to CHF111.6m, with costs carefully controlled. Basilea ended the year with a strong balance sheet and net cash CHF 86.9m.